Adaptive Biotechnologies Corporation

Equities

ADPT

US00650F1093

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.6 ^USD	-0.38%		+8.33%	-46.94%

Apr. 05	Adaptive Biotechnologies Corporation Announces Preliminary Unaudited Revenue Results for the First Quarter Ended March 31, 2024	CI
Apr. 03	Adaptive Biotechnologies Corporation Announces CFO Changes	CI

Adaptive Biotechnologies Corporation Updates Revenue Guidance for the Full Year 2023

November 09, 2023 at 04:15 pm EST

Adaptive Biotechnologies Corporation updated revenue guidance for the full year 2023. The company is updating full year 2023 revenue guidance to exclude revenue from the Immune Medicine business. MRD business full year 2023 revenue to be in the range of $100 million to $105 million.

Latest news about Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation Announces Preliminary Unaudited Revenue Results for the First Quarter Ended March 31, 2024	Apr. 05	CI
Adaptive Biotechnologies Corporation Announces CFO Changes	Apr. 02	CI
Adaptive Biotechnologies Reports Preliminary Q1 Revenue, Appoints Kyle Piskel as CFO	Apr. 02	MT
Transcript : Adaptive Biotechnologies Corporation - Special Call	Apr. 02
Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024	Apr. 02	CI
JPMorgan Adjusts Price Target on Adaptive Biotechnologies to $8 From $11, Maintains Overweight Rating	Feb. 15	MT
Adaptive Biotechnologies' Q4 Loss Widens; Revenue Declines; Shares Down	Feb. 15	MT
Transcript : Adaptive Biotechnologies Corporation, Q4 2023 Earnings Call, Feb 14, 2024	Feb. 14
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q4 Revenue $45.8M, vs. Street Est of $48.5M	Feb. 14	MT
Adaptive Biotechnologies Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 14	CI
Transcript : Adaptive Biotechnologies Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 01:30 PM	Jan. 09
Adaptive Biotechnologies Corporation and Collaborators to Present More Than 30 Abstracts Demonstrating the Actionability of ClonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th Annual Meeting	Dec. 05	CI
Adaptive Biotechnologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Transcript : Adaptive Biotechnologies Corporation, Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Reports Q3 Revenue $37.9M, vs. Street Est of $43M	Nov. 09	MT
Adaptive Biotechnologies Corporation Updates Revenue Guidance for the Full Year 2023	Nov. 09	CI
Adaptive Biotechnologies Partners With BeiGene on Minimal Residual Disease Testing of Potential Treatments for Lymphoid Malignancies	Nov. 07	MT
Adaptive Biotechnologies Corporation Announces New Translational Collaboration to Measure Minimal Residual Disease with Clonoseq(R) Assay Across Beigene's Lymphoid Malignancy Pipeline	Nov. 07	CI
Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating	23-10-24	MT
BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating	23-10-20	MT
Transcript : Adaptive Biotechnologies Corporation Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 01:35 PM	23-09-13
Adaptive Biotechnologies Corporation Announces Launch of Epic Integration for ClonosEQ	23-09-13	CI
Adaptive Biotechnologies Corporation Announces Kevin Conroy Resigns from the Board	23-09-01	CI
Insider Sell: Adaptive Biotechnologies	23-08-08	MT
Adaptive Biotechnologies Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI

Chart Adaptive Biotechnologies Corporation

Duration

Period

Chart Adaptive Biotechnologies Corporation

More charts

Company Profile

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patientâs immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Adaptive Biotechnologies Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.6 USD

Average target price

6.667 USD

Spread / Average Target

+156.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.94%	383M
EXACT SCIENCES CORPORATION	-20.45%	10.82B
IOVANCE BIOTHERAPEUTICS, INC.	+43.17%	3.25B
GUARDANT HEALTH, INC.	-35.86%	2.11B
BGI GENOMICS CO., LTD.	-17.21%	2.08B
VERACYTE, INC.	-29.81%	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.56%	1.02B
SEEGENE, INC.	-4.37%	733M
CAREDX, INC	-37.00%	391M
CURIOX BIOSYSTEMS CO., LTD	+13.32%	332M

Bio Diagnostics & Testing